JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement ...

InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now. As May came to an end, InflaRx announced that its ...

Key takeaways: Ulcerative pyoderma gangrenosum is a rare disease with no current treatment. Vilobelimab has been granted orphan drug and fast track designations by the FDA. InflaRx has initiated a ...

Pyoderma gangrenosum is an ulcerating disorder of the skin with sterile neutrophilic inflammation that may be seen in up to 5% of patients with chronic ulceration of the legs. 1 Typically painful, it ...

Pyoderma Gangrenosum: Pain Identified as Reliable Patient-Reported Outcome Doug Brunk September 21, 2023 0 ...

Afsaneh Alavi, M.D., Associate Professor of Dermatology at the Mayo Clinic and Coordinating Principal Investigator of the study, will give a late-breaker oral presentation entitled, “Anti-C5a antibody ...